| The protein kinase Cβ–selective inhibitor, enzastaurin (LY317615. HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon … JR Graff, AM McNulty, KR Hanna, BW Konicek, RL Lynch, SN Bailey, ... Cancer research 65 (16), 7462-7469, 2005 | 512 | 2005 |
| Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity JR Graff, BW Konicek, TM Vincent, RL Lynch, D Monteith, SN Weir, ... The Journal of clinical investigation 117 (9), 2638-2648, 2007 | 465 | 2007 |
| An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines JD Davidson, L Ma, M Flagella, S Geeganage, LM Gelbert, CA Slapak Cancer research 64 (11), 3761-3766, 2004 | 429 | 2004 |
| Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential … B Tan, DA Young, ZH Lu, T Wang, TI Meier, RL Shepard, K Roth, Y Zhai, ... Journal of Biological Chemistry 288 (5), 3500-3511, 2013 | 209 | 2013 |
| The folate pathway inhibitor pemetrexed pleiotropically enhances effects of cancer immunotherapy DA Schaer, S Geeganage, N Amaladas, ZH Lu, ER Rasmussen, A Sonyi, ... Clinical cancer research 25 (23), 7175-7188, 2019 | 114 | 2019 |
| Basics of enzymatic assays for HTS HB Brooks, S Geeganage, SD Kahl, C Montrose, S Sittampalam, ... Assay Guidance Manual [Internet], 2012 | 102 | 2012 |
| A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumours A Tolcher, J Goldman, A Patnaik, KP Papadopoulos, P Westwood, ... European Journal of Cancer 50 (5), 867-875, 2014 | 64 | 2014 |
| Inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, leads to altered carbohydrate metabolism in cancer cells B Tan, S Dong, RL Shepard, L Kays, KD Roth, S Geeganage, MS Kuo, ... Journal of Biological Chemistry 290 (25), 15812-15824, 2015 | 56 | 2015 |
| Akt1 and akt3 exert opposing roles in the regulation of vascular tumor growth TL Phung, W Du, Q Xue, S Ayyaswamy, D Gerald, Z Antonello, S Nhek, ... Cancer research 75 (1), 40-50, 2015 | 53 | 2015 |
| Discovery of a highly selective NAMPT inhibitor that demonstrates robust efficacy and improved retinal toxicity with nicotinic acid coadministration G Zhao, CF Green, YH Hui, L Prieto, R Shepard, S Dong, T Wang, B Tan, ... Molecular cancer therapeutics 16 (12), 2677-2688, 2017 | 48 | 2017 |
| Significance of metal ions in galactose-1-phosphate uridylyltransferase: an essential structural zinc and a nonessential structural iron S Geeganage, PA Frey Biochemistry 38 (40), 13398-13406, 1999 | 29 | 1999 |
| Transient kinetics of formation and reaction of the uridylyl-enzyme form of galactose-1-P uridylyltransferase and its Q168R-variant: insight into the molecular basis of … S Geeganage, PA Frey Biochemistry 37 (41), 14500-14507, 1998 | 28 | 1998 |
| Discovery of N-(6-Fluoro-1-oxo-1,2-dihydroisoquinolin-7-yl)-5-[(3R)-3-hydroxypyrrolidin-1-yl]thiophene-2-sulfonamide (LSN 3213128), a Potent and Selective … KR Fales, FG Njoroge, HB Brooks, S Thibodeaux, A Torrado, C Si, JL Toth, ... Journal of Medicinal Chemistry 60 (23), 9599-9616, 2017 | 27 | 2017 |
| Identification and characterization of the IDO1 inhibitor LY3381916 FC Dorsey, KA Benhadji, LL Sams, DA Young, JF Schindler, KL Huss, ... Cancer Research 78 (13_Supplement), 5245-5245, 2018 | 18 | 2018 |
| A phase I study of an IDO-1 inhibitor (LY3381916) as monotherapy and in combination with an anti-PD-L1 antibody (LY3300054) in patients with advanced cancer N Kotecki, P Vuagnat, BH O’Neil, S Jalal, S Rottey, H Prenen, ... Journal of Immunotherapy 44 (7), 264-275, 2021 | 15 | 2021 |
| Characterization of a novel AICARFT inhibitor which potently elevates ZMP and has anti-tumor activity in murine models HB Brooks, TI Meier, S Geeganage, KR Fales, KJ Thrasher, SA Konicek, ... Scientific Reports 8 (1), 15458, 2018 | 14 | 2018 |
| Pemetrexed enhances anti-tumor efficacy of PD1 pathway blockade by promoting intra tumor immune response via immunogenic tumor cell death and T cell intrinsic mechanisms R Novosiadly, D Schaer, N Amaladas, E Rasmussen, ZH Lu, A Sonyi, ... Cancer Research 78 (13_Supplement), 4549-4549, 2018 | 13 | 2018 |
| Discovery of chiral dihydropyridopyrimidinones as potent, selective and orally bioavailable inhibitors of AKT S Parthasarathy, K Henry, H Pei, J Clayton, M Rempala, D Johns, ... Bioorganic & medicinal chemistry letters 28 (10), 1887-1891, 2018 | 12 | 2018 |
| Abstract LB-274: identification and characterization of LY3410738, a novel covalent inhibitor of cancer-associated mutant Isocitrate Dehydrogenase 1 (IDH1) N Brooks, R DeWalt, S Boulet, ZH Lu, L Kays, R Cavitt, S Gomez, ... Cancer Research 79 (13_Supplement), LB-274-LB-274, 2019 | 11 | 2019 |
| Kinetic Mechanism of UDP-Hexose Synthase, a Point Variant of Hexose-1-Phosphate Uridylyltransferase from Escherichia coli FJ Ruzicka, S Geeganage, PA Frey Biochemistry 37 (32), 11385-11392, 1998 | 11 | 1998 |
